Loading...

PR Information Data

AdipoLABs hosts a Seminar at KIMES for a Cancer Treatment Based on Hyperthermia : 2018.03.12
18-03-12 09:21 3,501회 0건

3696653844_1576196403.907.jpg

2018 KIMES Seminar for Medical Staff, Cancer Patients and Their Families


AdipoLABs (CEO Han Sung-ho), a specialist in hyperthermia cancer treatment device has announced on March 12th that it will hold a special seminar on 'Necessity of cancer treatment and the case report using hyperthermia therapy device' at 2018 KIMES at COEX, Seoul on the 16th of March.

AdipoLABs will set up a booth at the 2018 KIMES which will be held from the 15th to exhibit 'REMISSION 1'. The seminar will be held separately near the exhibition hall on the 3rd floor of COEX. It is a place to announce some improvement cases when cancer treatment is conducted with 'REMISSION 1'.

During this special seminar, there will be speeches from Dr. Il-bong Choi, Chairman of the Korean Society for Thermal Medicine, Dr. Hong-suk Jang, and Dr. Young-nam Kang from the Department of Radiation Oncology at The Catholic University Seoul St. Mary Hospital, Dr. Jong-chun Joo from Won Kwang University, and finally professor Soo-jung Park from Woo Seok University.

They will discuss the basic principles of hyperthermia, cancer and hyperthermia, hyperthermia and immunity, treatment of Korean cancer-therapy, and the effects and the positive results of high-frequency hyperthermia.

To participate in the seminar, families need to select and pre-register a seminar related to 'Hyperthermia Therapy Device REMISSION 1' from the seminars of March 16th at KIMES 2018 using mobile or computer website. It is an open seminar that can be attended by medical staff, event participants, cancer patients and their families.

AdipoLABs decided to speed up the promotion of 'REMISSION 1' with this exhibition and seminar.

Han Sung-ho, CEO of AdipoLABs, said, “Korean movie star, Shin Seong-il, who has recently been diagnosed with the third stage of lung cancer, has been receiving cancer rehabilitation treatment for a long time with REMISSION 1and immunotherapy.” "'REMISSION 1' is a cancer medical device developed with pure domestic technology," he added. "REMISSION 1comes from a small company, but if the proper support comes from government and related industry, REMISSION 1will be able to reach the global market soon."

'REMISSION 1' is a cancer treatment equipment developed by a sole domestic engineering of Korean company AdipoLABs. In 2015, the Ministry of Food and Drug Safety in South Korea issued a license for cancer treatment to AdipoLABs. The high frequency of 0.46Mhz is energized in the patient's body and helps to improve human immunity with deep heat and by necrosis of cancer since cancer cells are weaker in heat than normal cells. So far, about 40 hospitals have trusted this device.